| Source: |
|
Federal Grant |
| Clinical Trial Description: |
|
Patients with HIV |
| Principal Investigator: |
|
Stephen T. Bartlett, M.D. |
| |
|
|
|
| Source: |
|
Novartis |
| Clinical Trial Description: |
|
A 24-month, multi-center, randomized, open-label non-inferiority
study of the efficacy and safety comparing two concentration-controlled
Certican regimens with reduced Neoral versus Myfortic with standard
dose Neoral in de novo renal transplant recipients |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
|
| |
|
|
| Source: |
|
Pfizer |
| Clinical Trial Description: |
|
A Phase 2 randomized , multicenter, active comparator-controlled
trial to evaluate the safety and efficacy of coadministration of CP-690,550
and Mycophenolate Mofetil/Mycophenolate Sodium in de novo kidney allograft
recipients (A3921030) |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
|
| |
|
|
| Source: |
|
Alavita |
| Clinical Trial Description: |
|
Phase 2, two-part study of the safety and tolerability
of diannexin in kidney transplant recipients |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
|
| |
|
|
| Source: |
|
Astellas |
| Clinical Trial Description: |
|
A phase 2, randomized, open-label, parallel group, multi-center
study to assess the safety and efficacy of alefacept in de novo kidney
transplant recipients |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
|
| |
|
|
| Source: |
|
Wyeth |
| Clinical Trial Description: |
|
A randomized, open-label, comparative evaluation of conversion
from calcineurin inhibitor treatment to sirolimus treatment versus continued
calcineurin inhibitor treatment in liver allograft recipients undergoing
maintenance therapy |
| Principal Investigator: |
|
Luis Campos, M.D. |
| |
|
|
|
| Source: |
|
Novartis |
| Clinical Trial Description: |
|
A 4-week multicenter, double-blind, randomized, parallel
group study to compare the gastrointestinal safety and tolerability
of myfortic and Cellcept when administered in combination with calcineurin
inhibitors in renal transplant recipients experiencing gastrointestinal
intolerance |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
|
| |
|
|
| Source: |
|
Novartis |
| Clinical Trial Description: |
|
A retrospective study comparing outcomes and costs associated
with gastrointestinal side effects of myfortic v. Cellcept in renal
transplant recipients |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
|
| |
|
|
| Source: |
|
Novartis |
| Clinical Trial Description: |
|
A facilitated access program to provide everolimus for
maintenance patients completing therapy in RAD trials in solid organ
transplantation |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
|
| |
|
|
| Source: |
|
Novartis |
| Clinical Trial Description: |
|
"Predictors of Allograft Outcomes Relating to Optimal
Induction and Immunosuppressive Regimens for Populations at High Immunological
Risk for Poorer Allograft Outcomes" |
| Principal Investigator: |
|
Benjamin Philosophe, M.D., Ph.D. |
| |
|
|
| Clinical Trial Description: |
|
A screening protocol and research registry for the clinical
research unit at the University of Maryland Division of Transplantation |
| Principal Investigator: |
|
Matthew Cooper, M.D. |
Email this Page
Print this Page 
Print this page
Email this page
Twitter
Facebook
YouTube
